"..it's just fish oil and all the studies show it does no good and even causes prostate cancer. .."
Not to mention the damage it could do to human heart valves considering the damage it can do to older roundup sprayer valves. A valve is a valve is a valve... and a fish oil study is a fish oil study is a fish oil sturdy...
Only in America would these arguments reside outside the dumb & dumber zone.
Congrats on learning to tie your show laces - still hard to believe you mastered that incredible feat!
There is a new problem for Vascepa. It seems when Vascepa pills are mixed with Roundup, a common product in many households, damage may result to the sprayer valves in many older sprayers, costing hundreds of dollars to repair. Adam F. is bringing this urgent data to the attention of the advisory committee.
Do I need a smiley - better safe than sorry.
Could I borrow your list? I like them as reasons to buy.
7 trading days before Adcom issues its decision. Are you feeling lucky. Will Adcom actually use the bs like that Italian study to decide or bore us all by using Vascepa's Anchor triial results? Will Adam's crazy bs turn out to be right or will Adcom do what' it's supposed to do and consider the trials data?
The real asset here in the technology to develop a broad range of respiratory products. IMHO, a buyout pps could be north of $15 or around $850M.
Unfortunately, that would still leave many long term holders with large losses. Such was the mismanagement here!
"Here is the problem: Amarin is asking the FDA to allow them to sell Vascepa to the public as a product that WILL BENEFIT THEM by improving their health (lowering cv events)."
There you go again, trying to add apples and oranges.
The SPA says nothing about improving health. The subject of the binding SPA contract between Amarin and the FDA is lipid management. The panel will be asked to vote on whether they believe Vascepa is effective in lipid management and whether the safety profile is acceptable. It's really that simple not that the Reduce-It stipulation is put to bed.
If the market assumed a 25% chance the panel would vote in favor of approval, the pps should be at least $15. It is rare for the market to be as wrong as we think it is. This has all the signs of information that has not been disclosed being the hands of a few. It looks very similar to the situation with SAC Capital and Elan, and Biogen prior to the bapi data release. There may be shenanigans involved here as well.
There's a chance the pps will now advance. It was very difficult for retail investors to go long AMRN after reading the garbage coming from NIA, day in day out.
I think ccur is worth around $10 if they continue to be profitable.
and the pps has not budged. All this despite incontrovertible phase 3 data with a pristine safety profile.
Ladies & gentlemen, I put to you we do not have an orderly market here! Perhaps we should delist and relist on the NYSE.